Bio-Techne Corp. (TECH) Financials
Key financial figures for Bio-Techne Corp. (Q1 2027).
Bio-Techne's fiscal Q1 2027 net sales rose 5% to $299.7 million (7% organic), but GAAP diluted EPS fell to $0.18 from $0.24 on higher SG&A as the pending Merck KGaA merger awaits closing. Net sales were $299.7 million for the quarter ended September 30, 2026, up 5% from $286.6 million a year earlier; organic revenue grew 7%, with the prior-year held-for-sale business a 2% drag and currency immaterial (10-Q MD&A). GAAP operating income was $36.6 million versus $47.7 million a year earlier, and GAAP diluted EPS was $0.18 versus $0.24; selling, general and administrative expense rose 15% to $133.7 million and R&D rose 9% to $26.3 million. GAAP gross margin was 65.6% in both periods. Figures are for Q1 FY2027, as Bio-Techne reported them.
- Revenue
- $300M
- Net Income
- $28M
- EPS
- $0.18
- Total Assets
- $2.6B
- Operating Cash Flow
- $73M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q1 FY2027 | $300M | $28M | $0.18 | 12.21% | $67M |
| Q4 FY2026 | $321M | $55M | $0.36 | 23.13% | $87M |
| Q3 FY2026 | $311M | $51M | $0.32 | 24.24% | $78M |
| Q2 FY2026 | $296M | $38M | $0.24 | 18.41% | $76M |
| Q1 FY2026 | $287M | $38M | $0.24 | 16.63% | $22M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2026 | $1.2B | $182M | $1.16 | 20.73% | $263M |
| FY2025 | $1.2B | $73M | $0.46 | 8.38% | $257M |
| FY2024 | $1.2B | $168M | $1.05 | 17.83% | $236M |
Frequently asked questions
What was Bio-Techne's revenue last quarter?
Bio-Techne reported revenue of $299.7 million for Q1 FY2027, up 4.6% from the same period a year earlier.
Is Bio-Techne profitable?
Yes. Bio-Techne reported net income of $28.3 million for Q1 FY2027, a net margin of 9.44% on revenue.
How has Bio-Techne's margin trended?
Operating margin was 12.21% in Q1 FY2027, compared with 16.63% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Bio-Techne generate?
Bio-Techne generated free cash flow of $67.2 million in Q1 FY2027, after capital expenditure.
Full income statement, balance sheet and cash flow for Bio-Techne Corp. on SentiSense, with up to forty quarters and twenty fiscal years of history.